Skip to main content
Her Health Peptides

Medical disclaimer: This site is educational and does not provide individualized medical advice. Always consult a licensed clinician about your situation.

Share

Melanocortin-4 receptor agonist (peptide)

Setmelanotide

Brand names: Imcivree

Last reviewed 2026-08-01
Women included; analysis limitedPregnancy/lactation data limited

Setmelanotide is approved for specific rare genetic obesity disorders. Women's health evidence beyond the approved populations is limited.

Key takeaways

  • Approved for rare genetic obesity syndromes with confirmed variants.
  • Pregnancy, lactation, and long-term women's health data are limited.

Mechanism and pathway

Activates melanocortin-4 receptors to reduce appetite and body weight in rare genetic obesity.

Peptide relationship: Setmelanotide is an MC4R peptide agonist.

Route and formulation: Subcutaneous injection

Author

Ian Gauntt

RN, BSN — 10 years as a critical care nurse

Medical reviewer

Medical Reviewer (Pending Assignment)

Medical review pending assignment by a licensed clinician.

Last reviewed 2026-08-01Next review 2026-11-01

Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.

Questions for Your ClinicianCompare medicines

The Women's Evidence Brief — one audit, one update, one evidence lesson each week.

Join the list